Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06776341

Natural History Study of GEMIN-5 Related Neurodevelopmental Disorder

This study will include a comprehensive retrospective chart review and a longitudinal prospective observational natural history study to characterize the phenotypic spectrum of GEMIN5-Related Neurodevelopmental Disorder. We aim to define the trajectory of this ultra-rare disease, core clinical features, characteristics at disease onset and diagnosis, neurological symptomatology, and neuroimaging findings over time. In this study, biological specimens (serum) will also be collected in a biorepository for translational research purposes.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, 15224, United States

Location status: Recruiting

Location contact

Deepa Soundara Rajan, MD

SUB_INVESTIGATOR

Kate Kielty, MD

CONTACT

[email protected]

412-692-6350

About this study

This study will include individuals across the lifespan with molecularly confirmed GEMIN5 biallelic mutations.

This study will be ongoing indefinitely.

There are three main components to the study as are detailed below:

  • A retrospective chart review of UPMC medical records and other institutions' medical records, for all patients in the study. Families/patients will provide staff with a signed Release of Information, so that we can obtain a copy of the participants complete medical record which will be requested from previously treating physicians. This may include records from several disciplines, for example neurological and physical exams, neurodevelopmental testing (cognitive, motor, language and daily living skills), growth parameters, results to previous genetic testing, MRI, lab results including lumbar puncture studies, audiologic exam, vision screening, nerve conduction studies, ophthalmologic exam, swallow studies, co-morbidities, and family history.
  • An observational, longitudinal prospective study of patients seen at the UPMC Center for Neuogenomics (CCNG) clinic. Clinical data obtained as part of a typical CCNG visit include vital signs, measurements (weight, head circumference, length), a developmental history, neurodevelopmental testing (eg. cognitive, speech and language, motor skills, developmental skills, vision, hearing), and a comprehensive neurological exam, including an ataxia rating scale. Additionally, any neurodiagnostic results obtained clinically are reviewed if available, such as MRI brain and spine, EEG, and nerve conductions studies.
  • Patients who are seen at the CCNG clinic in person may opt to submit an optional research biological samples.

Primary endpoint:

Neurodevelopmental outcomes

Secondary endpoint (if available):

MRI - presence of cerebellar atrophy Survival Vision Hearing Biomarkers of disease

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals with molecularly confirmed GEMIN5 biallelic mutations, ages 0 years and above

Exclusion criteria

  • none

Treatment and study plan

GEMIN5-Related Neurodevelopmental Disorder

Other

This is an observational study. The investigators will collect data from participants' medical records regarding neurodevelopmental outcomes (eg. cognitive, speech and language, motor skills, developmental skills, vision, hearing), Time to event (Acquistion and loss of developmental milestones), and, if available, data regarding MRIs (presence of cerebellar atrophy), survival, visiion, hearing, and biomarkers of disease.

Primary outcomes

  1. neurodevelopmental outcomes

    Time frame: 26 years

    time to acquisition and/or loss of milestones

Secondary outcomes

  1. MRI

    Time frame: 26 years

    presence of cerebellar atrophy

  2. Survival

    Time frame: 26 years

    age at death

  3. Vision

    Time frame: 26 years

    presence of ocular pathology

  4. Hearing

    Time frame: 26 years

    presence of hearing loss

  5. Biomarkers of disease

    Time frame: 26 years

    Biomarkers of disease

Study contacts

Contact information is provided by the study sponsor or research team.

Kate Kielty, MD

CONTACT

[email protected]

412-692-6350

Sponsors and collaborators

Lead sponsor

University of Pittsburgh

Other

Registry information

Official study title

Retrospective and Longitudinal Prospective Natural History Study of GEMIN5-Related Neurodevelopmental Disorder

Important dates

Study start
2025
Primary completion
2050
Study completion
2050
First posted
Jan 15, 2025
Registry last updated
Jul 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.